Poolbeg Pharma Future Growth
Future criteria checks 0/6
Poolbeg Pharma's earnings are forecast to decline at 13.1% per annum. EPS is expected to decline by 11.7% per annum.
Key information
-13.1%
Earnings growth rate
-11.7%
EPS growth rate
| Pharmaceuticals earnings growth | 21.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -6 | -6 | -5 | 2 |
| 12/31/2024 | N/A | -6 | -6 | -6 | 2 |
| 6/30/2024 | N/A | -4 | -5 | -4 | N/A |
| 3/31/2024 | N/A | -4 | -5 | -4 | N/A |
| 12/31/2023 | N/A | -4 | -5 | -4 | N/A |
| 9/30/2023 | N/A | -4 | -5 | -5 | N/A |
| 6/30/2023 | N/A | -5 | -5 | -5 | N/A |
| 3/31/2023 | N/A | -5 | -5 | -5 | N/A |
| 12/31/2022 | N/A | -5 | -5 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7JN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 7JN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 7JN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 7JN's revenue is forecast to grow faster than the German market.
High Growth Revenue: 7JN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 7JN's Return on Equity is forecast to be high in 3 years time